Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

A Phase II study for ocular rosacea is set to begin in late 2025, with data expected in 2026. Tarsus aims to expand physician education to identify Demodex blepharitis in broader patient categories.

Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the ...

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the "Company” or "Tarsus”) today announced the pricing of an upsized ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

A Phase II study for ocular rosacea is set to begin in late 2025, with data expected in 2026. Tarsus aims to expand physician education to identify Demodex blepharitis in broader patient categories.

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Trusted, comprehensive information to help you get on the path to clear skin.